Emergency Approval Mechanisms for Human Vaccines in India

Area of Science:

• Regulatory Science
• Public Health Policy
• Vaccine Development

Background:

• The COVID-19 pandemic exposed global vulnerabilities in managing public health emergencies (PHEs).
• Timely access to medical therapeutics, particularly vaccines, proved critical during the pandemic.
• India implemented emergency approval pathways, including rolling and accelerated reviews, to expedite vaccine access.

Purpose of the Study:

• To examine the use of India's New Drugs and Clinical Trials Rules 2019 for emergency COVID-19 vaccine approvals.
• To explore the legal foundation for emergency vaccine authorization during PHEs in India.
• To identify challenges and intricacies within India's existing 'emergency use' framework.

Main Methods:

• Review of the New Drugs and Clinical Trials Rules 2019.
• Analysis of the Drug Controller General of India's (DCGI) emergency approval processes for COVID-19 vaccines.
• Assessment of the legislative basis for emergency use authorization.

Main Results:

• The New Drugs and Clinical Trials Rules 2019 provided a framework for emergency COVID-19 vaccine approvals in India.
• Regulatory flexibility, digital integration, and adapted statistical methods were employed.
• The study identified critical aspects of the 'emergency use' paradigm: definition, decision-making transparency, and termination rules.

Conclusions:

• The Indian regulatory framework demonstrated adaptability during the COVID-19 PHE.
• Policy recommendations are proposed to strengthen the 'emergency use' framework for future public health threats.
• Enhancing the definition, decision-making transparency, and termination protocols for emergency use is crucial.